DME drug continues to impress

Article

iCo-007, the experimental intravitreal injection for the treatment of diabetic macular oedema (DME), has produced pleasing interim trial results and been approved to progress to the third stage of the Phase I study, according to a statement released by the drug's licence holder, iCo Therapeutics Inc.

iCo-007, the experimental intravitreal injection for the treatment of diabetic macular oedema (DME), has produced pleasing interim trial results and been approved to progress to the third stage of the Phase I study, according to a statement released by the drug's licence holder, iCo Therapeutics Inc.

iCo-007 - designed and discovered by ISIS Pharmaceuticals Inc for the treatment of DME and diabetic retinopathy (DR) - is a second-generation antisense inhibitor, which targets not vascular endothelial growth factor (VEGF) but the Raf isoform c-Raf kinase mRNA, and may also prove to be a viable treatment for certain oncology indications.

The open-label, dose-escalation study, which is assessing the mechanism of iCo-007 in sufferers of diffuse DME and not healthy volunteers, has a primary endpoint of establishing safety and tolerability in diffuse DME patients; the study will also monitor pharmacokinetics, retinal thickness and visual acuity. At this mid-point of the trial, administration of iCo-007 is not associated with any serious adverse events.

Recent Videos
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
© 2025 MJH Life Sciences

All rights reserved.